Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Report provides global picture of wide inequalities in care for women's cancers

2.

HER3 Antibody Drug Conjugate Shows Promise in NSCLC

3.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

4.

The Cherenkov color image shows the possibility of improving the quality of radiation therapy.

5.

From 40 to 74, the US Preventive Services Task Force advises every two years for screening mammography.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot